2009
Does Oral Antiandrogen Use Before Leuteinizing Hormone-releasing Hormone Therapy in Patients With Metastatic Prostate Cancer Prevent Clinical Consequences of a Testosterone Flare?
Oh W, Landrum M, Lamont E, McNeil B, Keating N. Does Oral Antiandrogen Use Before Leuteinizing Hormone-releasing Hormone Therapy in Patients With Metastatic Prostate Cancer Prevent Clinical Consequences of a Testosterone Flare? Urology 2009, 75: 642-647. PMID: 19962733, DOI: 10.1016/j.urology.2009.08.008.Peer-Reviewed Original ResearchConceptsLeuteinizing hormone-releasing hormone agonistsSpinal cord compressionBladder outlet obstructionMetastatic prostate cancerCord compressionOral antiandrogensAntiandrogen therapyAntiandrogen useLeuteinizing hormone-releasing hormoneOutlet obstructionProstate cancerAgonist treatmentNarcotic prescriptionsRate of spinal cord compressionAssess spinal cord compressionMetastatic prostate cancer patientsClinical disease flaresProstate cancer patientsHormone-releasing hormoneTestosterone flareRadiation therapyClinical flareHormone therapyAgonist therapyLHRH agonist
2003
Hormonal Therapy in Postmenopausal Women with Breast Cancer
Campos SM, Winer EP. Hormonal Therapy in Postmenopausal Women with Breast Cancer. Oncology 2003, 64: 289-299. PMID: 12759523, DOI: 10.1159/000070284.Peer-Reviewed Original ResearchConceptsFirst-line agentsBreast cancerPostmenopausal womenEffective palliationAromatase inhibitorsAdvanced disease settingsEarly breast cancerMetastatic breast cancerNeoadjuvant settingAdvanced diseaseHormonal therapyLHRH agonistPositive tumorsPure antiestrogenMetastatic breastPresent treatment approachesTreatment approachesDisease settingsCancerWomenPalliationPatientsAntiestrogensInhibitorsTreatment
2002
The Evolving Role of Estrogen Therapy in Prostate Cancer
Oh W. The Evolving Role of Estrogen Therapy in Prostate Cancer. Clinical Genitourinary Cancer 2002, 1: 81-89. PMID: 15046698, DOI: 10.3816/cgc.2002.n.009.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAndrogen AntagonistsDiethylstilbestrolDose-Response Relationship, DrugDrug Administration ScheduleDrug Resistance, NeoplasmEstrogensFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingProstate-Specific AntigenProstatic NeoplasmsRandomized Controlled Trials as TopicRisk AssessmentTreatment OutcomeConceptsLuteinizing hormone-releasing hormoneEstrogen therapyProstate cancerAndrogen-independent prostate cancer patientsHepatic first-pass metabolismNormal prostate developmentOral estrogen therapyToxicity of diethylstilbestrolNormal prostate epitheliumParenteral route of administrationMetastatic prostate cancerPhase II trialProstate-specific antigenProstate cancer patientsSafety of EstrogensRisk of thromboembolismHormone-releasing hormoneFirst-pass metabolismPrimary medical treatmentActivity of diethylstilbestrolRoute of administrationProstate developmentProstate epitheliumDevelopment of cancerLHRH agonist
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply